AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-22. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
=== Venetoclax === BCL-2 is a cellular protein that can act to inhibit cell death due to apoptosis. The BCL-2 gene appears to be one of the most up-regulated (i.e. overactive) genes in BPDCN. Venetoclax inhibits the apoptosis-inhibiting action of BCL-2 and proved active in treating two patients with relapsed or refractory BPDCN. A phase I clinical trial testing the safety and efficacy of the drug in BPDCN is planned but not yet in its recruiting phase.
== Interactions == Catalase has been shown to interact with the ABL2 and Abl genes. Infection with the murine leukemia virus causes catalase activity to decline in the lungs, heart and kidneys of mice. Conversely, dietary fish oil increased catalase activity in the heart, and kidneys of mice.
=== Informants and holdouts === Also targeted were civilians suspected of being informants of the apartheid police. Alongside petrol bombs, necklacing became a favoured method of executing such suspects. In one early example known nationwide, a young woman in Duduza, Maki Skosana, was necklaced on 20 July 1985 at a funeral for a local activist; a television crew filmed a crowd of young men kicking and beating her, tearing her clothes off, dousing her in petrol, and then setting her alight while one man rammed a glass bottle into her vagina. Skosana was rumoured to be the girlfriend and co-conspirator of Joe Mamasela, a notorious askari who had killed several Duduza youths by hand grenade in an entrapment operation in June. In addition, though mass action had broad support during this period, there were frequently complaints that the reluctant were compelled to participate in stay-aways or boycotts by force or intimidation. Groups of COSAS supports were accused of "erecting barricades to prevent residents from going to work; attacking those who tried to do so; moving from school to school ordering students out of class; hurling stones and petrol bombs at policemen; attacking buses and taxis; digging trenches in the streets; destroying buildings; and assaulting members of rival organisations". There was also evidence that vigilante attacks were sometimes perpetrated on the basis of mere political or personal "grudges".
Sources: en.wikipedia.org
Type 1 and 2 5α reductase enzymes are present at pilosebaceous units in papillae of individual hair follicles. They catalyse formation of the androgens testosterone and DHT, which in turn regulate hair growth. Androgens have different effects at different follicles: they stimulate IGF-1 at facial hair, causing hair regrowth, but stimulate TGF β1, TGF β2, dickkopf1 and IL-6 at the scalp, causing hair follicle miniaturisation. Female androgenic alopecia is characterized by diffuse crown thinning without hairline recession, and like its male counterpart rarely leads to total hair loss. Finasteride and minoxidil are usually first line therapy for its treatment. Other options include topical or systemic spironolactone or flutamide, although they have a high incidence of feminising side effects and are better tolerated in female androgenic hair loss. More advanced cases may be resistant or unresponsive to medical therapy, however, and require hair transplantation. Naturally occurring units of one to four hairs, called follicular units, are excised and moved to areas of hair restoration. These follicular units are surgically implanted in the scalp in close proximity and in large numbers. The grafts are obtained from either Follicular Unit Transplantation (FUT) – colloquially referred to as "strip harvesting" – or Follicular Unit Extraction (FUE). In the former, a strip of skin with follicular units is extracted and dissected into individual follicular unit grafts. The surgeon then implants the grafts into small incisions, called recipient sites.
Supratrochlear nerve and the supraorbital nerve from the ophthalmic division of the trigeminal nerve Greater occipital nerve (C2) posteriorly up to the vertex Lesser occipital nerve (C2) behind the ear Zygomaticotemporal nerve from the maxillary division of the trigeminal nerve supplying the hairless temple Auriculotemporal nerve from the mandibular division of the trigeminal nerve The innervation of scalp can be remembered using the mnemonic 'Z-GLASS' for Zygomaticotemporal nerve, Greater occipital nerve, Lesser occipital nerve, Auriculotemporal nerve, Supratrochlear nerve, and Supraorbital nerve. The motor innervation of the scalp, specifically, the occipitofrontalis muscle, is split into two main factions: the frontal belly or frontalis muscle is supplied by the temporal branch of facial nerve, while the occipital belly or occipitalis is supplied by the posterior auricular branch of facial nerve.
=== As a feed additive === Guanidinoacetic acid is a nutritional feed additive approved by the European Commission for chickens for fattening, weaned piglets and pigs for fattening. It is supposed to lead with a "vegetarian diet" (meaning without feeding of animal protein) to higher feed conversion, higher weight gain and improved muscle increase already at a low dosage (600 g/to feed). Possible benefits of glycocyamine supplementation can not yet be conclusively assessed, neither in other breeding, fattening and domestic animals nor for high-performance athletes, analogous to the glycocyamine metabolite creatine. The simultaneous intake of methyl providing substances such as betaine appears advisable because of the risk of homocysteine formation with glycocyamine alone.
In 1922, German anti-Semitic theorist Alfred Rosenberg in his primary contribution to Nazi theory on Zionism, Der Staatsfeindliche Zionismus ("Zionism, the Enemy of the State"), accused German Zionists of working for a German defeat and supporting Britain and the implementation of the Balfour Declaration, in a version of the stab-in-the-back myth. Adolf Hitler took a similar approach in some of his speeches from 1920 onwards.
Sources: en.wikipedia.org
Ozata DM, Gainetdinov I, Zoch A, Phillip D, Zamore PD (2019). "PIWI-Interacting RNAs: Small RNAs With Big Functions" (PDF). Nature Reviews Genetics. 20 (2): 89–108. doi:10.1038/s41576-018-0073-3. hdl:20.500.11820/9f12a0e2-1d56-4a44-968d-6f6300efa2b6. PMID 30446728. S2CID 53565676. Secondary source, 2019 Marc S, Weinberg; Kevin V, Morris (August 2016). "Transcriptional Gene Silencing in Humans". Nucleic Acids Research. 44 (14): 6505–6517. doi:10.1093/nar/gkw139. PMC 5001580. PMID 27060137. Secondary source, 2016 Carthew RW, Sontheimer EJ (February 2009). "Origins and Mechanisms of miRNAs and siRNAs". Cell. 136 (4): 642–55. doi:10.1016/j.cell.2009.01.035. PMC 2675692. PMID 19239886. Secondary source, 2009 Hannon GJ, Rossi JJ (September 2004). "Unlocking the Potential of the Human Genome With RNA Interference". Nature. 431 (7006): 371–8. Bibcode:2004Natur.431..371H. doi:10.1038/nature02870. PMID 15372045. S2CID 4410723. Secondary source, 2004
O'Conner won 158,590 votes to Ayyadurai's 104,782, Ayyadurai alleged that over one million ballots had been destroyed and that the state had committed election fraud. He alleged that ballot images had to be preserved for 22 months and were now missing. However, MIT political science professor Charles Stewart stated that federal law only requires that physical ballots be stored. Harvard law professor Nicholas Stephanopoulos disputed Ayyadurai's allegation of fraud and a spokesperson for the state accused him of spreading misinformation. Fact checkers at Reuters and the Associated Press labelled the allegations as false. On February 1, 2021, Ayyadurai was suspended from Twitter. On February 3, he filed a lawsuit against Massachusetts politician William Galvin and other Massachusetts election officials, alleging that they were responsible for Twitter's suspending him. On August 10, Ayyadurai dropped the lawsuit along with an October 2020 suit against Galvin.
I'm here not only because John is a dream candidate, but because I'm living in the end game in the United States and it's not funny. Canada is starting the same sort of right-wing, corporate ownership of government, corporate tradeoffs with government, smear campaigns, "let's lower the corporate tax rate without mentioning it's going to up the private tax rates." It's happening in Canada. God forbid if anyone should bring up privatizing health care.
== Development == Sally Green submitted Half Bad to an agent in January 2013; in March, editorial director Ben Horslen acquired the manuscript for Penguin Books children's imprint Puffin Books, billing it "the book of the Bologna Children's Book Fair" after a six-figure bidding war. In the run up to its publication in the UK on March 3, 2014, international rights to Half Bad sold rapidly; within 13 weeks of acquisition, it had sold in 25 territories; by November 2013, 36. On publication day, it broke the Guinness World Record for 'Most Translated Book by a Debut Author, Pre-publication' with 45 different translations.
=== Genes in other plants === CLE genes have been found in numerous monocots, dicots, and even moss. Research has even shown that some plants, like rice, contain the presence of a multi-CLE domain. Various CLE-like genes have also been found in the genomes of plant-parasitic nematodes such as beet, soybean and potato cyst nematodes.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.